KANJINTI 150 mg prašek za koncentrat za raztopino za infundiranje
Trastuzumab
Composition and organoleptic properties
| Name | Role | Strength | Strength expression |
|---|---|---|---|
| trastuzumab | — | 150 mg/1 prašek | — |
Organoleptic description—
Drug status
Temporary cessation of marketing of the medicinal product.
Last drug update date:9. 7. 2026